Horizon Discovery Group plc Director/PDMR Shareholding (2175N)

TIDMHZD

RNS Number : 2175N

Horizon Discovery Group plc

07 August 2017

Horizon Discovery Group plc

Director/PDMR Shareholding

Cambridge, UK, 7 August 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the "Company"), a global leader in the application of gene editing technologies, today announces that Richard Vellacott, Chief Financial Officer, was granted options under the Horizon Discovery 2014 Sharesave Scheme over Horizon Discovery Group plc ordinary shares of 1p each as detailed below:

 
              No. of          Option      Exercisable 
               shares          Exercise    Date 
               under option    Price 
 Richard      10,638          GBP1.692    1 September 
  Vellacott                                2020 
 
 

In addition, Mr. Vellacott and Dr Darrin Disley, Chief Executive Officer, have exercised options under the Horizon Discovery 2014 Sharesave Scheme over Horizon Discovery Group plc ordinary shares of 1p each as a result of which their shareholdings have increased as detailed below:

 
               Number        Option      Exercise   No. of 
                of options    Exercise               ordinary 
                exercised     Price                  shares 
                and shares                           held in 
                retained                             the Company 
                                                     following 
                                                     this transaction 
 Richard                                 7 August 
  Vellacott    10,869        GBP1.656     2017      37,869 
 Darrin                                  7 August 
  Disley       10,869        GBP1.656     2017      725,392 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  ---------------------------------------------------------- 
 a)   Name                    Richard Vellacott 
---  -----------------  --------------------------------------- 
 2    Reason for the notification 
---  ---------------------------------------------------------- 
 a)   Position/status               Chief Financial Officer 
---  -----------------  --------------------------------------- 
 b)   Initial            Initial notification 
       notification 
       /Amendment 
---  -----------------  --------------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ---------------------------------------------------------- 
 a)   Name               Horizon Discovery Group plc 
---  -----------------  --------------------------------------- 
 b)   LEI                213800L812B9NI5M3G89 
---  -----------------  --------------------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ---------------------------------------------------------- 
 a)   Description        Ordinary Shares of GBP0.01 each 
       of the 
       financial          ISIN: GB00BK8FL363 
       instrument, 
       type of 
       instrument 
       Identification 
       code 
---  -----------------  --------------------------------------- 
 b)   Nature                  1. Grant of options 
       of the                  2. Exercise of options 
       transaction 
---  -----------------  --------------------------------------- 
 c)   Currency                GBP 
---  -----------------  --------------------------------------- 
 d)   Price(s)             Price               No. of 
       and volume(s)                             shares 
                           ------------------  ---------------- 
                                 1. GBP1.692         1. 10,638 
                                  2. GBP1.656         2. 10,869 
                           ------------------  ---------------- 
---  -----------------  --------------------------------------- 
 e)   Aggregated 
       information 
       - Aggregated        N/A 
       volume              N/A 
       - Price 
---  -----------------  --------------------------------------- 
 f)   Date of            1. 4 August 2017 
       the transaction 
                          2. 7 August 2017 
---  -----------------  --------------------------------------- 
 g)   Place of           London Stock Exchange, AIM 
       the transaction 
---  -----------------  --------------------------------------- 
 
 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  ------------------------------------------------------ 
 a)   Name                    Dr Darrin Disley 
---  -----------------  ----------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------ 
 a)   Position/status               Chief Executive Officer 
---  -----------------  ----------------------------------- 
 b)   Initial            Initial notification 
       notification 
       /Amendment 
---  -----------------  ----------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ------------------------------------------------------ 
 a)   Name               Horizon Discovery Group plc 
---  -----------------  ----------------------------------- 
 b)   LEI                213800L812B9NI5M3G89 
---  -----------------  ----------------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ------------------------------------------------------ 
 a)   Description        Ordinary Shares of GBP0.01 each 
       of the 
       financial          ISIN: GB00BK8FL363 
       instrument, 
       type of 
       instrument 
       Identification 
       code 
---  -----------------  ----------------------------------- 
 b)   Nature                   Exercise of options 
       of the 
       transaction 
---  -----------------  ----------------------------------- 
 c)   Currency                GBP 
---  -----------------  ----------------------------------- 
 d)   Price(s)             Price       No. of shares 
       and volume(s)       ----------  -------------- 
                            GBP1.656    10,869 
                           ----------  -------------- 
---  -----------------  ----------------------------------- 
 e)   Aggregated 
       information 
       - Aggregated        N/A 
       volume              N/A 
       - Price 
---  -----------------  ----------------------------------- 
 f)   Date of            7 August 2017 
       the transaction 
---  -----------------  ----------------------------------- 
 g)   Place of           London Stock Exchange, AIM 
       the transaction 
---  -----------------  ----------------------------------- 
 

- ENDS -

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Darrin Disley, Chief Executive Officer

Richard Vellacott, Chief Financial Officer

Chris Claxton, VP Investor Relations

Tel: [phone]

Numis Securities Limited (Broker and NOMAD)

Michael Meade

Freddie Barnfield

Tom Ballard

Tel: [phone]

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa Gardiner

Tel: [phone]

Email: [e-mail]

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a leading global gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.

Horizon's core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN, CRISPR and Transposon) able to alter almost any gene sequence in human or mammalian cell-lines.

Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon's commercial offering has been adopted by over 1,600 unique research organisations in over 50 countries as well as in the Company's own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEQLFBDVFEBBV

(END) Dow Jones Newswires

August 07, 2017 02:00 ET (06:00 GMT)